Search
CANVAS is a commitment by the Governments of Australia and New Zealand to advance the development of a vaccine against GAS infection, which can cause rheumatic fever.
NHMRC funding has been awarded for 4 years to Murdoch Childrens Research Institute for this project, with collaboration from Professor Jonathan Carapetis at The Kids.
END RHD is an alliance of health, research and community organisations seeking to amplify efforts to end rheumatic heart disease in Australia through advocacy and engagement.
Kimberley Aboriginal Medical Services, Nirrumbuk Environmental Health and Services and The Kids Research Institute Australia seek to implement and evaluate a community-led project, funded by the Department of Health, to prevent and manage RHD in a selected high-risk Aboriginal community
The END RHD Communities approach uses community-led, research-backed prevention strategies to tackle Strep A skin and throat infections, acute rheumatic fever and rheumatic heart disease
Continued progress in controlling RHD requires an understanding of how to improve delivery of regular injections of penicillin - secondary prophylaxis (SP).
This is a 6 month cohort study involving participants at Princess Margaret Hospital prescribed BPG for secondary prophylaxis of RHD.
Group A Streptococcus (Strep A) causes a wide spectrum of diseases, ranging from pharyngitis and impetigo to severe invasive infections and immune-mediated conditions such as acute rheumatic fever, rheumatic heart disease and acute post-streptococcal glomerulonephritis. Contemporary data on the global burden of Strep A diseases are lacking.
Acute rheumatic fever (ARF), a serious inflammatory condition, often leads to rheumatic heart disease. Between 2011 and 2016, Aotearoa New Zealand implemented a rheumatic fever prevention programme to reduce high rates of ARF through improved community access to timely diagnosis and early treatment of group A streptococcal pharyngitis, which has been shown to prevent subsequent ARF.
To determine population-based rates of non-fatal complications of rheumatic heart disease (RHD).